Preliminary Opinion on the Safety of Breast Implants in Relation To
Total Page:16
File Type:pdf, Size:1020Kb
Breast implant safety and Anaplastic Large Cell Lymphoma Preliminary Opinion 1 2 3 4 5 6 7 8 Scientific Committee on Health, Environmental and Emerging Risks 9 (SCHEER) 10 11 12 13 14 15 Preliminary Opinion 16 on the safety of breast implants 17 in relation to anaplastic large cell lymphoma 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 The SCHEER adopted this Opinion at its plenary meeting on 8 October 2020 33 34 Breast implants safety and Anaplastic Large Cell Lymphoma Preliminary Opinion _________________________________________________________________________________________ 1 2 ABSTRACT 3 4 The SCHEER was requested by the European Commission to provide a scientific opinion on 5 the safety of breast implants in relation to anaplastic large cell lymphoma (ALCL). 6 7 Literature searches were carried out using PubMed and Find-eR. The publication period 8 covered was from 1 September 2016 to 31 August 2019, and an additional search was 9 performed early in 2020 covering the period from 1 September 2019 to 30 April 2020. In 10 addition, relevant sources and literature beyond this period was considered as well. After 11 excluding all irrelevant papers and duplicate papers, a total of 605 papers remained and 12 were evaluated for this Scientific Opinion. 13 14 BIA-ALCL is the occurrence of ALCL adjacent to a breast implant. Diagnosis of BIA-ALCL is 15 achieved by analysis of seroma fluid or if a mass, core needle, incisional or excisional tissue 16 biopsy. Radical en bloc surgical resection (i.e. implant including seroma and intact capsule) 17 with safe margins, including healthy tissue, is recommended as the standard of care 18 treatment, with a very good prognosis. The incidence of BIA-ALCL is considered low, varies 19 by implant type, and is mainly associated with textured implants. However, estimates of 20 incidence have significant limitations related to the frequent use of ad hoc reporting of 21 cases compared with systematic reporting, and the use of sales data provided by 22 manufacturers. Surface textures of breast implants are not all manufactured in the same 23 way. Overall there is a moderate level of evidence for a causal relationship between 24 textured breast implants and ALCL; however, the pathogenic mechanisms are not well 25 understood; current hypotheses include genetic predisposition, bacterial contamination 26 resulting in chronic inflammation, shell shedding of particulates resulting in chronic 27 inflammation, shell surface characteristics leading to friction resulting in inflammation, and 28 implant associated reactive compounds. The disease latency varies between a few to 20 29 or even more years. There are several alternatives to breast implants that involve plastic 30 surgery techniques, either using autologous flap tissue or autologous fat transfer. 31 32 There is a need for further research to better understand the aetiology and pathogenesis 33 of BIA-ALCL. Reporting of new BIA-ALCL cases by the relevant registries is also of major 34 importance to obtain a better estimate of the risk of BIA-ALCL for patients with a breast 35 implant. 36 37 Keywords: breast implants, anaplastic large cell lymphoma, cancer, BIA-ALCL 38 39 Opinion to be cited as: 40 41 SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Scientific 42 Opinion on the safety of breast implants in relation to anaplastic large cell lymphoma, 8 43 October 2020 44 _________________________________________________________________________________________ 2 Breast implants safety and Anaplastic Large Cell Lymphoma Preliminary Opinion _________________________________________________________________________________________ 1 2 ACKNOWLEDGMENTS 3 4 5 Members of the Working Group are acknowledged for their valuable contribution to this 6 scientific advice. The members of the Working Group are: 7 8 9 The SCHEER members: 10 11 Roberto Bertollini 12 Wim H De Jong (Chair) 13 Demosthenes Panagiotakos (Rapporteur) 14 Ana Proykova 15 Theodoros Samaras 16 17 18 The external experts: 19 20 Mark Clemens (The University of Texas MD Anderson Cancer Center, Houston, USA) 21 Daphne De Jong (Amsterdam UMC, VU University Medical Center, Amsterdam, The 22 Netherlands) 23 Ingrid Hopper (Monash University, Melbourne, Australia) 24 Hinne Rakhorst (Medisch Spectrum Twente, Enschede, The Netherlands) 25 Fabio Santanelli di Pompeo (Sapienza University of Rome, Rome, Italy) 26 Suzanne Turner (University of Cambridge, UK) 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 All Declarations of Working Group members are available at the following webpage: 43 Register of Commission expert groups and other similar entities 44 45 46 47 48 49 50 51 52 53 54 _________________________________________________________________________________________ 3 Breast implants safety and Anaplastic Large Cell Lymphoma Preliminary Opinion _________________________________________________________________________________________ 1 2 About the Scientific Committees (2016-2021) 3 Two independent non-food Scientific Committees provide the Commission with the 4 scientific advice it needs when preparing policy and proposals relating to consumer safety, 5 public health and the environment. The Committees also draw the Commission's attention 6 to the new or emerging problems, which may pose an actual or potential threat. 7 These committees are the Scientific Committee on Consumer Safety (SCCS) and the 8 Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), both of 9 which are composed of scientists appointed in their personal capacity. 10 In addition, the Commission relies upon the work of other Union bodies, such as the 11 European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the 12 European Centre for Disease Prevention and Control (ECDC) and the European Chemicals 13 Agency (ECHA). 14 15 SCHEER 16 This Committee, on request of Commission services, provides Opinions on questions 17 concerning health, environmental and emerging risks. The Committees addresses 18 questions on: 19 - health and environmental risks related to pollutants in the environmental media and other 20 biological and physical factors in relation to air quality, water, waste and soils. 21 22 - complex or multidisciplinary issues requiring a comprehensive assessment of risks to 23 consumer safety or public health, for example antimicrobial resistance, nanotechnologies, 24 medical devices and physical hazards such as noise and electromagnetic fields. 25 26 SCHEER members 27 Roberto Bertollini, Teresa Borges, Wim de Jong, Pim de Voogt, Raquel Duarte-Davidson, 28 Peter Hoet, Rodica Mariana Ion, Renate Kraetke, Demosthenes Panagiotakos, Ana 29 Proykova, Theodoros Samaras, Marian Scott, Emanuela Testai, Theo Vermeire, Marco 30 Vighi, Sergej Zacharov 31 32 Contact 33 European Commission 34 Health and Food Safety 35 Directorate C: Public Health 36 Unit C2: Health information and integration in all policies 37 L-2920 Luxembourg 38 [email protected] 39 40 ©European Union, 2020 41 42 PDF ISBN xxx-xx-xx-xxxxx-x ISSN xxxx-xxxx doi:10.xxxx/xx...x xx-xx-xx-xxx-xx-x 43 44 Luxembourg: Publications Office of the European Union, 45 46 47 The Opinions of the Scientific Committees present the views of the independent 48 scientists who are members of the committees. They do not necessarily reflect the 49 views of the European Commission. The Opinions are published by the European 50 Commission in their original language only. 51 52 http://ec.europa.eu/health/scientific_committees/policy/index_en.htm 53 54 55 _________________________________________________________________________________________ 4 Breast implants safety and Anaplastic Large Cell Lymphoma Preliminary Opinion _________________________________________________________________________________________ 1 2 TABLE OF CONTENTS 3 4 ABSTRACT .......................................................................................................... 2 5 ACKNOWLEDGMENTS ........................................................................................... 3 6 1. MANDATE FROM THE EU COMMISSION SERVICES ............................................ 6 7 1.1 Background ................................................................................................ 6 8 1.2 Terms of Reference ..................................................................................... 7 9 2. CONCLUSIONS ................................................................................................. 8 10 2.1 Answers to the Terms of References .................................................................. 9 11 3. MINORITY OPINION ........................................................................................ 12 12 4. INTRODUCTION ............................................................................................. 13 13 4.1 Use of breast implants ................................................................................... 13 14 4.2 Types of breast implants ................................................................................ 14 15 4.3 Alternatives to breast implants ....................................................................... 15 16 4.4 Breast Implant Associated - Anaplastic Large Cell Lymphoma .............................. 17 17 4.4.1. Anaplastic Large Cell Lymphoma (ALCL) ....................................................... 17 18 4.4.2. Breast Implant Associated – Anaplastic Large Cell Lymphoma (BIA-ALCL) ......... 18 19 4.5 Treatment and prognosis of Breast Implant Associated - Anaplastic